SG11201901624RA - Lysine specific histone demethylase-1 inhibitors and uses therefor - Google Patents

Lysine specific histone demethylase-1 inhibitors and uses therefor

Info

Publication number
SG11201901624RA
SG11201901624RA SG11201901624RA SG11201901624RA SG11201901624RA SG 11201901624R A SG11201901624R A SG 11201901624RA SG 11201901624R A SG11201901624R A SG 11201901624RA SG 11201901624R A SG11201901624R A SG 11201901624RA SG 11201901624R A SG11201901624R A SG 11201901624RA
Authority
SG
Singapore
Prior art keywords
international
inhibitors
pct
histone demethylase
specific histone
Prior art date
Application number
SG11201901624RA
Inventor
Sudha Rao
Peter Milburn
Original Assignee
Univ Canberra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016903602A external-priority patent/AU2016903602A0/en
Application filed by Univ Canberra filed Critical Univ Canberra
Publication of SG11201901624RA publication Critical patent/SG11201901624RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 15 March 2018 (15.03.2018) WIPO I PCT (51) International Patent Classification: A61K 38/43 (2006.01) A61P 35/00 (2006.01) A61K 38/16 (2006.01) (21) International Application Number: PCT/AU2017/050969 (22) International Filing Date: 07 September 2017 (07.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2016903602 07 September 2016 (07.09.2016) AU (71) Applicant: UNIVERSITY OF CANBERRA [AU/AU]; University Drive, Bruce, Australian Capital Territory 2617 (AU). (72) Inventors: RAO, Sudha; 102 Buxton Street, Deakin, Aus- tralian Capital Territory 2600 (AU). MILBURN, Peter; 8 Miller Street, O'Connor, Australian Capital Territory 2602 (AU). (74) Agent: DAVIES COLLISON CAVE PTY LTD; Level 10, 301 Coronation Drive, Milton, Queensland 4064 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) O (54) Title: LYSINE SPECIFIC HISTONE DEMETHYLASE-1 INHIBITORS AND USES THEREFOR cc (57) : Disclosed are lysine specific histone demethylase-1 (LSD1) inhibitors in methods and compositions for immune check- O point inhibition. The invention also relates to proteinaceous molecules and their use in altering at least one of (i) formation, (ii) 5 proliferation, (iii) maintenance, (iv) epithelial to mesenchymal cell transition (EMT), or (v) mesenchymal to epithelial cell transition C (MET) of an LSD1 overexpressing cell. omit VIII °nolo olommoomiommo oimIE (10) International Publication Number WO 2018/045422 Al
SG11201901624RA 2016-09-07 2017-09-07 Lysine specific histone demethylase-1 inhibitors and uses therefor SG11201901624RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016903602A AU2016903602A0 (en) 2016-09-07 Inhibitors and uses therefor
PCT/AU2017/050969 WO2018045422A1 (en) 2016-09-07 2017-09-07 Lysine specific histone demethylase-1 inhibitors and uses therefor

Publications (1)

Publication Number Publication Date
SG11201901624RA true SG11201901624RA (en) 2019-03-28

Family

ID=61561256

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201901624RA SG11201901624RA (en) 2016-09-07 2017-09-07 Lysine specific histone demethylase-1 inhibitors and uses therefor

Country Status (8)

Country Link
US (1) US20220040280A1 (en)
EP (1) EP3509627A4 (en)
JP (1) JP2019534317A (en)
CN (1) CN110312522A (en)
AU (1) AU2017323868A1 (en)
CA (1) CA3035806A1 (en)
SG (1) SG11201901624RA (en)
WO (1) WO2018045422A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3636284A1 (en) * 2018-10-11 2020-04-15 NBE Therapeutics AG Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications
CN110142068B (en) * 2019-06-12 2024-02-02 杭州华得森生物技术有限公司 Kit and method for detecting epithelial and mesenchymal mixed circulating tumor cells
KR20220054644A (en) * 2019-09-03 2022-05-03 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 Methods and Agents for Determining Patient Condition
CN112326961B (en) * 2020-10-30 2021-08-06 福州迈新生物技术开发有限公司 Analysis method and storage device for proportion of PD-L1 positive tumor cells in non-small cell lung cancer
WO2023067058A1 (en) * 2021-10-20 2023-04-27 Queen Mary University Of London Sequential treatments and biomarkers to reverse resistance to kinase inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1833981B1 (en) * 2004-12-16 2012-04-18 President and Fellows of Harvard College Histone demethylation mediated by the nuclear amine oxidase homolog lsd1
WO2007006581A2 (en) * 2005-07-13 2007-01-18 Universitätsklinikum Freiburg Targeting lsd1 for use in identifying and/or scoring prostate cancer and for controlling anrogen receptor-dependent gene expression
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
JP2013540767A (en) * 2010-10-07 2013-11-07 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ Compositions and methods for modulating immunodeficiency virus transcription
US20150267176A1 (en) * 2012-10-12 2015-09-24 The General Hospital Corporation Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
SG11201510369WA (en) * 2013-06-25 2016-01-28 Univ Canberra Methods and compositions for modulating cancer stem cells
US9186391B2 (en) * 2013-08-29 2015-11-17 Musc Foundation For Research Development Cyclic peptide inhibitors of lysine-specific demethylase 1
CA2958704A1 (en) * 2014-08-25 2016-03-03 University Of Canberra Compositions for modulating cancer stem cells and uses therefor
ES2944597T3 (en) * 2015-12-30 2023-06-22 Novartis Ag Enhanced Efficacy Immune Effector Cell Therapies

Also Published As

Publication number Publication date
CA3035806A1 (en) 2018-03-15
AU2017323868A1 (en) 2019-03-21
JP2019534317A (en) 2019-11-28
EP3509627A4 (en) 2020-05-06
CN110312522A (en) 2019-10-08
WO2018045422A1 (en) 2018-03-15
EP3509627A1 (en) 2019-07-17
US20220040280A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
SG11201901624RA (en) Lysine specific histone demethylase-1 inhibitors and uses therefor
SG11201909432SA (en) Compounds for increasing genome editing efficiency
SG11201808990QA (en) Compositions for topical application of compounds
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201900799XA (en) Pyridopyrimdinone cdk2/4/6 inhibitors
SG11201804915RA (en) Methods for treating huntington's disease
SG11201806650VA (en) Systems and methods for providing a personal distributed ledger
SG11201810611YA (en) Coumarin compounds and their uses as fluorescent labels
SG11201900743UA (en) Multiple function exercise device
SG11201806758VA (en) Vcn enhancer compositions and methods of using the same
SG11201900501RA (en) Cannabis composition
SG11201909011PA (en) Niraparib compositions
SG11201808476SA (en) Recycling of polymer matrix composite
SG11201906959RA (en) Aryl hydrocarbon receptor (ahr) modulator compounds
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201904535VA (en) Prevention and treatment of bone and cartilage damage or disease
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201811161YA (en) Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
SG11201909837YA (en) Methods for treating lung disorders
SG11201806133UA (en) Intermediates in the synthesis of eribulin and related methods of synthesis
SG11201808675VA (en) Method and kit for the generation of dna libraries for massively parallel sequencing
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201906729RA (en) Topical cyclosporine-containing formulations and uses thereof
SG11201906963QA (en) Binding agents